Elite Pharma Q3 fiscal 2025 revenue $14.4M (-8% YoY); operating profit $1.1M (-69%)

ELITE PHARMACEUTICALS INC /NV/

2025-Q3 EPS reported -$0.02 revenue$52,047,656

Consolidated revenue $14.4M for quarter ended Dec 31, 2024, down 8% from $15.6M in prior-year period.
Operating profit fell 69% to $1.1M from $3.5M; company cites year-end holiday shipment delays.
Shipments delayed into first week of January 2025 due to timing differences at December holiday period.
No EPS, net income, or updated guidance provided in the release; conference call scheduled Feb 14.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.